Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
22
11
2021
accepted:
15
03
2022
pubmed:
3
4
2022
medline:
20
7
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis for several years (super-responders). To identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment. Patients registered in DERMBIO between January 2007 and November 2019 were included. Patients were categorized as being treatment refractory if they had had treatment failure to ≥3 biologics targeting ≥2 different pathways. Super-responders were patients treated with their first biologic for minimum 5 years without an absolute psoriasis area and severity index (PASI) > 3 between 6 months and 5 years of treatment. All remaining patients from DERMBIO served as comparators. In total, 3280 patients were included with a mean age of 45.0 years. 1221 (37%) of the patients were females. Of the included patients, 214 (6.5%) were categorized as treatment refractory and 207 (6.3%) were categorized as super-responders. Treatment refractory patients had higher mean body weight (100.6 kg vs. 90.6 kg, P < 0.0001) and higher mean BMI (32.2 vs. 29.4, P < 0.0001) compared with the rest of patients in DERMBIO. Super-responders had higher socioeconomic status and fewer comorbidities compared with the comparator group (P < 0.0001). A small proportion of patients with psoriasis treated with biologics are either super-responders or treatment refractory. Treatment refractory patients have higher body weight, whereas super-responders have fewer comorbidities and higher socioeconomic status.
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1284-1291Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet 2021; 397: 1301-1315.
Loft N, Egeberg A, Rasmussen MK et al. Response to biologics during the first six months of therapy in biologic-naïve patients with psoriasis predicts risk of disease flares: a Danish nationwide study. Acta Dermato-Venereologica 2020; 101: adv00357.
Piaserico S, Cazzaniga S, Chimenti S et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol 2014; 70: 257-262.e3.
Ortonne JP, Chimenti S, Reich K et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011; 25: 1012-1020.
Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol 2016; 75: 612-618.e6.
Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1040.
Rathod D, Weinberg JM, Yamauchi PS et al. Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report. J Drugs Dermatol 2019; 18: 394-396.
Armesto S, Vela CG, Sánchez J et al. Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatol Ther 2020; 33: e14464.
Thibodeaux Q, Ly K, Reddy V, Smith MP, Liao W. Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Reports 2019; 5: 928-930.
Galluzzo M, Andreani M, Testi M, Chimenti S, Talamonti M. HLA-C* 18: 01: A rare allele in the European Caucasian population coinciding with difficult-to-treat plaque psoriasis. Mol Diagn Ther 2016; 20: 227-230.
Xie KK, Braue A, Martyres R, Varigos G. Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments. Australas J Dermatol 2018; 59: e247-e252.
Yiu Z, Mason K, Hampton P et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020; 183: 294-302.
Zweegers J, Roosenboom B, van de Kerkhof P et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter Bio CAPTURE cohort. Br J Dermatol 2017; 176: 786-793.
Talamonti M, D'Adamio S, Galluccio T et al. High-resolution HLA typing identifies a new'super responder'subgroup of HLA-C* 06: 02-positive psoriatic patients: HLA-C* 06: 02/HLA-C* 04, in response to ustekinumab. J Eur Acad Dermatol Venereol 2019; 33: e364-e367.
Gniadecki R, Kragballe K, Dam T, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
Ahlehoff O, Skov L, Gislason G et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015; 29: 1128-1134.
Ahlehoff O, Skov L, Gislason G et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One 2012; 7: e36342.
Egeberg A, Iversen L, Gniadecki R et al. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis-nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol 2017; 31: 1183-1187.
Loft N, Skov L, Bryld L, Gislason G, Egeberg A. Treatment history of patients receiving biologic therapy for psoriasis-a Danish nationwide study. J Eur Acad Dermatol Venereol 2017; 31: e362-e363.
Loft ND, Skov L, Rasmussen MK et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PLoS One 2018; 13: e0192010.
Loft N, Skov L, Iversen L et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenom J 2018; 18: 494.
Gniadecki R, Bang B, Bryld L, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244-252.
Egeberg A, Ottosen M, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Dermato-Venereologica 2018; 98: 335-339.
Loft ND, Egeberg A, Rasmussen MK et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish Nationwide Study. Acta Dermato-Venereologica 2019; 99: 1224-1230.
Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 1-6.
Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-130.
Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28: 150-154.
Mahil S, Wilson N, Dand N et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2019; 182: 1158-1166.
Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of Ixekizumab to Etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Dermato-Venereologica 2019; 99: 971-977.
Warren R, Marsden A, Tomenson B et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol 2019; 180: 1069-1076.
Shalom G, Cohen A, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol 2020; 34: 1524-1528.
Petridis A, Panagakis P, Moustou E et al. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece. J Eur Acad Dermatol Venereol 2018; 32: 768-775.
Magis Q, Jullien D, Gaudy-Marqueste C et al. Predictors of long-term drug survival for infliximab in psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 96-101.
Schwarz CW, Loft N, Rasmussen MK et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish Nationwide Cohort Study. Acta Dermato-Venereologica 2021; 101: adv00579.
Mostafa N, Nader A, Noertersheuser P, Okun M, Awni W. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 490-497.
Wilkinson N, Tsakok T, Dand N et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol 2019; 139: 115-123.
Zorlu O, Bülbül Başkan E, Yazici S et al. Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatol Treat 2020; 33: 437-442.
Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol 2016; 55: 296-302.
Van den Reek J, Tummers M, Zweegers J et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol 2015; 29: 560-565.
Mahlich J, Alba A, El Hadad L, Leisten M-K, Peitsch WK. Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis. Adv Therapy 2019; 36: 1684-1699.
Gendelman O, Weitzman D, Rosenberg V, Shalev V, Chodick G, Amital H. Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. Br J Clin Pharmacol 2018; 84: 786-795.
Schaarschmidt M-L, Schmieder A, Umar N et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285-1294.
Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermat 2015; 135: 31-38.
Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 2021; 17: 81-97.